Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10019212 | 0.88 | EPHX2 (1.00) | EPHX2GAAHTTALDH1A1LMNA | |
| SCHEMBL21765926 | 0.80 | SLC13A5 (0.69) | EPHX2GAAALDH1A1LMNAPKM | |
| SCHEMBL10019219 | 0.79 | EPHX2 (1.00) | EPHX2GAAHTT | |
| SCHEMBL20258781 | 0.77 | PKM (0.74) | EPHX2GAAALDH1A1LMNAPKM | |
| SCHEMBL30924136 | 0.77 | SIGMAR1 (0.67) | EPHX2 | |
| SCHEMBL20509062 | 0.75 | RECQL (0.85) | EPHX2GAALMNAPKMRECQL | |
| SCHEMBL30924124 | 0.74 | EPHX2 (0.63) | EPHX2GAAHTT | |
| SCHEMBL30924045 | 0.74 | ACKR3 (0.62) | EPHX2GAAHTTCA12CA1 | |
| SCHEMBL13882047 | 0.74 | P2RX7 (0.61) | EPHX2GAAHTTALDH1A1LMNA | |
| SCHEMBL13876177 | 0.74 | EPHX2 (0.61) | EPHX2GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-26 | — | — | US | disclosed |
| US-9175285-B2 | Potent non-urea inhibitors of soluble epdxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-03 | — | — | US | disclosed |
| US-9175285-B2 | Potent non-urea inhibitors of soluble epdxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140349368-A1 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349368-A1 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-11-27 | — | — | US | disclosed |
| US-8653273-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653273-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120029022-A1 | Potent Non-Urea Inhibitors Of Soluble Epoxide Hydrolase | THE TRUSTEES OF COLUMBIA UNIVESITY IN THE CITY OF NEW YORK (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120029022-A1 | Potent Non-Urea Inhibitors Of Soluble Epoxide Hydrolase | THE TRUSTEES OF COLUMBIA UNIVESITY IN THE CITY OF NEW YORK (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010080183-A1 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349368-A1 | POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, ECE1 | EPHX2 2/4885GAA 2234/4885HTT 4409/4885 |
| US-20120029022-A1 | Potent Non-Urea Inhibitors Of Soluble Epoxide Hydrolase | EPHX1, EPHX2, ECE1 | EPHX2 2/4885GAA 2234/4885HTT 4409/4885 |
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | EPHX1, EPHX2, ECE1 | EPHX2 2/4885GAA 2234/4885HTT 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.